欧林生物
(688319)
| 流通市值：159.04亿 | | | 总市值：159.16亿 |
| 流通股本：4.05亿 | | | 总股本：4.06亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 157,803,808.92 | 704,160,325.32 | 506,920,470.94 | 305,849,689.82 |
| 营业收入 | 157,803,808.92 | 704,160,325.32 | 506,920,470.94 | 305,849,689.82 |
| 二、营业总成本 | 136,476,818.31 | 659,117,720.56 | 440,264,661.39 | 267,455,854.27 |
| 营业成本 | 12,874,679.08 | 49,579,783.45 | 34,993,613.76 | 20,889,102.06 |
| 税金及附加 | 2,609,283.33 | 6,052,593.97 | 3,305,954.34 | 2,477,746.03 |
| 销售费用 | 76,872,019.28 | 380,936,224.6 | 246,180,116.82 | 145,278,282.45 |
| 管理费用 | 19,719,862.19 | 75,161,385.81 | 50,362,440.62 | 32,902,561.01 |
| 研发费用 | 20,187,151.24 | 132,904,807.21 | 94,881,270.69 | 58,777,526.47 |
| 财务费用 | 4,213,823.19 | 14,482,925.52 | 10,541,265.16 | 7,130,636.25 |
| 其中:利息费用 | 4,120,209.37 | 14,644,287.81 | 10,815,243.51 | 7,455,488.08 |
| 其中:利息收入 | 79,925.01 | 603,556.94 | 551,837.97 | 425,415.39 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 125,136.99 | 497,841.77 | 259,436.3 | 150,511.64 |
| 资产处置收益 | - | 8,707.5 | 8,707.5 | 8,707.5 |
| 资产减值损失(新) | 5,635,839.5 | -13,585,517.39 | -3,558,183.17 | 491,601.37 |
| 信用减值损失(新) | 1,294,328.2 | -13,033,370.76 | -16,136,383.66 | -31,837,465.84 |
| 其他收益 | 4,010,106.65 | 11,926,905.6 | 8,376,168.21 | 7,484,305.7 |
| 四、营业利润 | 32,392,401.95 | 30,857,171.48 | 55,605,554.73 | 14,691,495.92 |
| 加:营业外收入 | 29,983.47 | 1,191,401.4 | 259,679.77 | 5,958.53 |
| 减:营业外支出 | - | 155,362.99 | 114,669.24 | 14,669.24 |
| 五、利润总额 | 32,422,385.42 | 31,893,209.89 | 55,750,565.26 | 14,682,785.21 |
| 减:所得税费用 | 5,224,670.74 | 9,994,472.7 | 8,602,256.82 | 1,452,994.79 |
| 六、净利润 | 27,197,714.68 | 21,898,737.19 | 47,148,308.44 | 13,229,790.42 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 27,197,714.68 | 21,898,737.19 | 47,148,308.44 | 13,229,790.42 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 27,189,316.87 | 22,260,140.53 | 47,479,767.98 | 13,196,891.47 |
| 少数股东损益 | 8,397.81 | -361,403.34 | -331,459.54 | 32,898.95 |
| 扣除非经常损益后的净利润 | 23,278,017.1 | 9,907,937.75 | 40,042,630.48 | 7,723,574.58 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.07 | 0.05 | 0.12 | 0.03 |
| (二)稀释每股收益 | 0.07 | 0.05 | 0.12 | 0.03 |
| 九、综合收益总额 | 27,197,714.68 | 21,898,737.19 | 47,148,308.44 | 13,229,790.42 |
| 归属于母公司股东的综合收益总额 | 27,189,316.87 | 22,260,140.53 | 47,479,767.98 | 13,196,891.47 |
| 归属于少数股东的综合收益总额 | 8,397.81 | -361,403.34 | -331,459.54 | 32,898.95 |
| 公告日期 | 2026-04-30 | 2026-03-31 | 2025-10-30 | 2025-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |